» Articles » PMID: 38111854

Alternatives to Topical Glaucoma Medication for Glaucoma Management

Overview
Journal Clin Ophthalmol
Publisher Dove Medical Press
Specialty Ophthalmology
Date 2023 Dec 19
PMID 38111854
Authors
Affiliations
Soon will be listed here.
Abstract

Topical glaucoma medications have favorable safety and efficacy, but their use is limited by factors such as side effects, nonadherence, costs, ocular surface disease, intraocular pressure fluctuations, diminished quality of life, and the inherent difficulty of penetrating the corneal surface. Although traditionally these limitations have been accepted as an inevitable part of glaucoma treatment, a rapidly-evolving arena of minimally invasive surgical and laser interventions has initiated the beginnings of a reevaluation of the glaucoma treatment paradigm. This reevaluation encompasses an overall shift away from the reactive, topical-medication-first default and a shift toward earlier intervention with laser or surgical therapies such as selective laser trabeculoplasty, sustained-release drug delivery, and micro-invasive glaucoma surgery. Aside from favorable safety, these interventions may have clinically important attributes such as consistent IOP control, cost-effectiveness, independence from patient adherence, prevention of disease progression, and improved quality of life.

Citing Articles

Travoprost Intracameral Implant in Eyes with Glaucoma or Ocular Hypertension: Early Short-Term Real-World Outcomes.

Teymoorian S, Kaur J Clin Ophthalmol. 2025; 19():157-166.

PMID: 39839758 PMC: 11747201. DOI: 10.2147/OPTH.S498431.


Third-Generation Trabecular Micro-Bypass Implantation with Phacoemulsification for Glaucoma.

Vest Z, Alinaghizadeh N, Prendergast C Ophthalmol Ther. 2025; 14(3):529-539.

PMID: 39812758 PMC: 11825416. DOI: 10.1007/s40123-024-01087-7.


An Emerging Multi-mechanism and Multi-modal Approach in Interventional Glaucoma Therapy.

Micheletti J, Shultz M, Singh I, Samuelson T Ophthalmol Ther. 2024; 14(1):13-22.

PMID: 39614979 PMC: 11724811. DOI: 10.1007/s40123-024-01073-z.


Interventional Glaucoma: Improving the Patient-Provider Educational Exchange.

Katz L, Myers J, Herndon L, Kresch Y, Hengerer F Clin Ophthalmol. 2024; 18:3365-3374.

PMID: 39588379 PMC: 11587800. DOI: 10.2147/OPTH.S491287.


Hyaluronate Protects From Benzalkonium Chloride-Induced Ocular Surface Toxicity.

Vereertbrugghen A, Pizzano M, Sabbione F, Del Papa M, Rodriguez G, Passerini M Transl Vis Sci Technol. 2024; 13(10):31.

PMID: 39432403 PMC: 11498636. DOI: 10.1167/tvst.13.10.31.


References
1.
Valente C, Iester M, Corsi E, Rolando M . Symptoms and signs of tear film dysfunction in glaucomatous patients. J Ocul Pharmacol Ther. 2011; 27(3):281-5. DOI: 10.1089/jop.2010.0133. View

2.
Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F . Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010; 29(4):312-34. DOI: 10.1016/j.preteyeres.2010.03.001. View

3.
Posarelli C, Ortenzio P, Ferreras A, Toro M, Passani A, Loiudice P . Twenty-Four-Hour Contact Lens Sensor Monitoring of Aqueous Humor Dynamics in Surgically or Medically Treated Glaucoma Patients. J Ophthalmol. 2019; 2019:9890831. PMC: 6369465. DOI: 10.1155/2019/9890831. View

4.
Sarkisian Jr S . Cochrane Reviews Regarding Minimally Invasive Glaucoma Surgical Techniques-Validity of Conclusions May Be Limited by Incomplete Evidence. JAMA Ophthalmol. 2021; 140(2):206-207. DOI: 10.1001/jamaophthalmol.2021.5397. View

5.
Kashiwagi K, Matsuda Y, Ito Y, Kawate H, Sakamoto M, Obi S . Investigation of visual and physical factors associated with inadequate instillation of eyedrops among patients with glaucoma. PLoS One. 2021; 16(5):e0251699. PMC: 8121298. DOI: 10.1371/journal.pone.0251699. View